DelveInsight’s, “Obesity Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.
In the Obesity pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Obesity NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key Takeaways from the Obesity Pipeline Report
- DelveInsight’s Obesity Pipeline report depicts a robust space with 100+ active players working to develop 130+ pipeline therapies for Obesity.
- The leading Obesity Companies include Novartis, Eli Lily &Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others
- Promising Obesity Therapies include VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others.
- The Obesity companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&D. The Obesity pipeline therapies under development are focused on novel approaches to treat/improve Obesity.
To explore more information on the latest breakthroughs in the Obesity Pipeline treatment landscape of the report, click here @ Obesity Pipeline Outlook
Obesity Overview
Obesity can be described as the “New World Syndrome”. Obesity is a multi-factorial disorder, which is often associated with many other significant diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers.
Recent Breakthroughs of Obesity Treatment Landscape
- Tirzepatide also known as LY3298176, (Dual GIP/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity. The dual agonist has also proven to be efficacious in tackling obesity and cardiovascular risk factors associated with T2D.
- Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.
- XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at Sciwind Biosciences. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in early clinical trials. . The drug is currently in phase 2 stage of development for the treatment of obesity.
- Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.
For further information, refer to the detailed Obesity Unmet Needs, Obesity Market Drivers, and Obesity Market Barriers, click here for Obesity Ongoing Clinical Trial Analysis
Obesity Emerging Drugs Profile
- Tirzepatide: Eli Lily & Company
- Danuglipron: Pfizer
- XW003: Sciwind Biosciences
- Noiiglutide: Jiangsu Hansoh Pharmaceutical
- MEDI 0382: MedImmune
Obesity Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.
Request a sample and discover the recent advances in Obesity Ongoing Clinical Trial Analysis and Medications, click here @ Obesity Treatment Landscape
Scope of the Obesity Pipeline Insight Report
- Coverage- Global
- Obesity Companies- Novartis, Eli Lily &Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others are evaluating novel Obesity treatment drugs candidate to improve the treatment landscape.
- Obesity Therapies- VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others
- Obesity Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Obesity Market Drivers and Obesity Market Barriers, click here @ Obesity Unmet Needs and Analyst Views
Table of Content
- Introduction
- Obesity Executive Summary
- Obesity Overview
- Obesity Pipeline Therapeutics
- Obesity Therapeutic Assessment
- Late Stage Products (Phase III)
- Oral Semaglutide: Novo Nordisk
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RZL-012: Raziel Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DD01: D&D Pharmatech
- Drug profiles in the detailed report…..
- Inactive Obesity Products
- Obesity Key Companies
- Obesity Key Products
- Obesity Unmet Needs
- Obesity Market Drivers
- Obesity Market Barriers
- Obesity Future Perspectives and Conclusion
- Obesity Analyst Views
- Obesity Key Companies
- Appendix
Got Queries? Find out the related information on Obesity Mergers and acquisitions, Obesity Licensing Activities @ Obesity Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/